Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05850611
Other study ID # IRCT20191228045924N3
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date April 30, 2023
Est. completion date September 21, 2024

Study information

Verified date October 2023
Source Mashhad University of Medical Sciences
Contact Daryoush Hamidi Alamdari, Ph.D
Phone +98 51 3882 8574
Email hamidiad@mums.ac.ir
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the chance of non-healing diabetic foot ulcers repair by improving the condition of lack of oxygen or hypoxia in the wound area caused by diabetes using methylene blue along with the use of platelet-rich plasma-fibrin glue as an effective treatment for wound healing.


Description:

The current study assesses the effects of methylene blue along with the use of platelet-rich plasma-fibrin glue on wound healing in patients with nonhealing diabetic foot ulcers (non-healing DFU). This randomized controlled trial is performed on 20 patients with non-healing DFU. Patients were treated with PRP-FG dressing plus 200 ml of oral methylene blue dissolved in milk(intervention group) or PRP-FG dressing plus placebo (200 ml of milk) (control group) for 4 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date September 21, 2024
Est. primary completion date August 21, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Having a Diabetic ulcer grade II and IV based on Wagner's classification on the sole, medial, or lateral part of the foot (including all surfaces of the toes) - Having a single ulcer on the feet and extremities (toes, soles, heels) with no significant reduction in ulcer size (<20%) despite the use of best treatment methods for at least four weeks - If there is more than one non-healing wound, choose the largest wound - The size of the wound surface (length × width) between 2 cm2 and 20 cm2 - No smoking, alcohol, and drug addiction based on the patient's self-report - Not taking drugs that may interfere with wound healing, such as Corticosteroids, immunosuppressants, and cytotoxic agents - Not having a concurrent chronic disease that may cause problems in wound healing, such as cancers, vasculitis, no history of known severe kidney, liver, and heart disease, such as liver cirrhosis, active hepatitis, dialysis, etc. - Not taking antidepressants - Insensitivity to milk lactose - Not having Glucose 6-phosphate dehydrogenase (G6PD) deficiency - Confirmed, informed, signed consent form - Ankle Brachial Index (ABI) higher than or equal to 0.7 Exclusion Criteria: - Do not be treated with methylene blue - The confirmed presence of osteomyelitis, or if there is suspicion of osteomyelitis - The subject is pregnant or intends to become pregnant during the test period - The patient is known to have mental, developmental, physical, and emotional disorders - The occurrence of certain medical conditions - The presence of a wound with a clear and severe infection, which is characterized by significant purulent secretions or extensive cellulitis, or gangrene requiring amputation - Evidence of venous, ischemic, neurotrophic ulcers (numbness, tingling, lack of Achilles tendon reflex) and traumatic wounds in the patient - Failure to refer the patient more than two times to the mentioned center for follow-up and dressing change - Hypersensitivity reaction to methylene blue - Platelet count less than 100,000 - The patient's lack of consent to continue cooperation

Study Design


Intervention

Drug:
Methylene Blue
The first intervention group includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention for 4 weeks.
Other:
Milk (control)
Group B will receive 200 ml of milk for 4 weeks.
Drug:
Methylene Blue and Platelet-Rich Plasma-Fibrin Glue
Group C will be undergone synergistic 4-week treatment with oral methylene blue and fibrin glue.
Other:
Milk and Platelet-Rich Plasma-Fibrin Glue (control)
Group D will be treated only with fibrin glue and 200 ml of milk for 4 weeks.

Locations

Country Name City State
Iran, Islamic Republic of Mashhad University of Medical Sciences Mashhad Razavi Khorasan

Sponsors (1)

Lead Sponsor Collaborator
Mashhad University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The healing rate of the ulcer Measurement of wound area with a ruler 4 weeks
Primary Wound Size Wound size will be measured with a ruler for length, and width as well as with digital imaging. Wound size will be assessed in digital images taken of the wound. 4 weeks
Secondary TcPO2 at baseline and after the intervention Transcutaneous oxygen tension (TcpO2) provides information about blood perfusion in the tissue immediately below the skin. (blood pressure, measured in millimeters of mercury (mmHg)) 4 weeks
Secondary Oxygen saturation at baseline and after the intervention Blood must contain a normal concentration of hemoglobin. that hemoglobin must be >95 % saturated with oxygen in arterial blood (sO2(a) >95 %) 4 weeks
Secondary Blood pressure (systolic and diastolic) The pressure of the blood in the circulatory system 4 weeks
Secondary The resting systolic toe pressure (TP) at baseline and after the intervention The toe cuff with the sphygmomanometer is slowly inflated until the waveform flattens (generally between 150-200 mmHg), then is inflated a further 20 mmHg. The cuff is slowly released at a rate of 2-5mmHg per second. The first regular cyclical waveform is considered the toe systolic pressure. 4 weeks
Secondary Serum IL-1ß levels at baseline and after the intervention Analysis of serum interleukin-1ß levels 4 weeks
Secondary Serum MCP-1 levels at baseline and after the intervention Analysis of serum monocyte chemoattractant protein-1 (MCP-1) levels 4 weeks
Secondary Serum TNF-a levels at baseline and after the intervention Analysis of serum tumor necrosis factor a (TNFa) levels 4 weeks
Secondary Serum IL-6 levels at baseline and after the intervention Analysis of serum interleukin-6 (IL-6) levels 4 weeks
Secondary Serum HIF-1a levels at baseline and after the intervention Analysis of serum hypoxia-inducible factor 1-alpha (HIF-1a) levels 4 weeks
Secondary Serum FBS levels at baseline and after the intervention Analysis of serum fasting blood sugar (FBS ) levels 4 weeks
Secondary Serum Insulin levels at baseline and after the intervention Analysis of Insulin levels 4 weeks
Secondary Lipid Profile at baseline and after the intervention Serum Triglyceride, Cholesterol, HDL, LDL, VLDL 4 weeks
Secondary Serum Urea at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum Creatinine at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum total bilirubin at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum Vitamin D levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary HbA1c at baseline and after the intervention Glycated hemoglobin 4 weeks
Secondary Serum Albumin (Alb) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Uric Acid levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum Homocysteine levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum ALT (alanine transaminase) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum AST (Aspartate Transferase) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum ALP (alkaline phosphatase) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum Met Hemoglobin levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum Hemoglobin (Hgb, Hb) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum white blood cells (WBCs) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum total Lymphocyte levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Platelet count at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Nitric oxide blood at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum lactate dehydrogenase (LDH) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum Erythrocyte Sedimentation Rate (ESR) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Serum C-Reactive Protein (CRP) levels at baseline and after the intervention In a quantitative laboratory method 4 weeks
Secondary Neutrophils count at baseline and after the intervention In a quantitative laboratory method 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT02652754 - Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers Phase 1
Completed NCT01070433 - A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers Phase 2
Completed NCT00971048 - Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds N/A
Terminated NCT00762138 - The AutoloGel™ Post-Market Surveillance (TAPS) Program N/A
Completed NCT00578604 - Non-Invasive Assessment of Wound Healing With Optical Methods N/A
Completed NCT05417425 - Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers Phase 1
Completed NCT02631512 - Evaluation of Woulgan in Diabetic Foot Ulcer Phase 4
Completed NCT02222376 - Effect of Topic Pirfenidone in Diabetic Ulcers Phase 3
Terminated NCT01816633 - Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers N/A
Completed NCT01221207 - Instant Total Contact Cast to Heal Diabetic Foot Ulcers N/A
Completed NCT01454401 - LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers N/A
Withdrawn NCT01105884 - Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers N/A
Completed NCT01291160 - Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers Phase 2/Phase 3
Completed NCT00536744 - Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers Phase 3
Terminated NCT00316537 - Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers Phase 1/Phase 2
Completed NCT00013299 - Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3 Phase 2
Completed NCT00013286 - A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk Phase 2
Terminated NCT02667327 - A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer Phase 3
Not yet recruiting NCT00916292 - Safety Study of Topical Human FGF-1 for Wound Healing Phase 1
Completed NCT01154374 - A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot) Phase 2